RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
1-Year Return
25.98%
This Quarter Return
+2.83%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.31B
AUM Growth
-$620M
(-16%)
Cap. Flow
-$396M
Cap. Flow
% of AUM
-11.94%
Top 10 Holdings %
Top 10 Hldgs %
35.65%
Holding
121
New
8
Increased
41
Reduced
28
Closed
10
Top Buys
| 1 |
Insmed
INSM
|
$54.2M |
| 2 |
Johnson & Johnson
JNJ
|
$24.8M |
| 3 |
Structure Therapeutics
GPCR
|
$23.1M |
| 4 |
UnitedHealth
UNH
|
$22.9M |
| 5 |
Eli Lilly
LLY
|
$16.5M |
Top Sells
| 1 |
Immunocore
IMCR
|
$66M |
| 2 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$44M |
| 3 |
Penumbra
PEN
|
$43.2M |
| 4 |
Boston Scientific
BSX
|
$32M |
| 5 |
Agios Pharmaceuticals
AGIO
|
$31.1M |
Sector Composition
| 1 | Healthcare | 97.63% |
| 2 | Consumer Staples | 1.87% |
| 3 | Industrials | 0.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Applied Therapeutics
APLT
$71.1M
| $7.26M | 0.22% |
1,555,004
+57,086
| +4% | +$267K |
|
77
Aurinia Pharmaceuticals
AUPH
$1.59B
| $6.74M | 0.2% |
1,179,740
+29,393
| +3% | +$168K |
|
78
Mersana Therapeutics
MRSN
$34.5M
| $6.12M | 0.18% |
121,871
| – | – |
|
79
Beam Therapeutics
BEAM
$1.82B
| $5.86M | 0.18% |
249,923
+102,413
| +69% | +$2.4M |
|
80
Acumen Pharmaceuticals
ABOS
$82.4M
| $5.57M | 0.17% |
2,300,059
| – | – |
|
81
Compass Therapeutics
CMPX
$458M
| $5.51M | 0.17% |
5,513,788
| – | – |
|
82
Apellis Pharmaceuticals
APLS
$3.49B
| $5.4M | 0.16% |
+140,700
| New | +$5.4M |
|
83
Fulcrum Therapeutics
FULC
$348M
| $4.51M | 0.14% |
727,673
| – | – |
|
84
MacroGenics
MGNX
$119M
| $4.48M | 0.13% |
1,053,647
-251,603
| -19% | -$1.07M |
|
85
Mineralys Therapeutics
MLYS
$2.04B
| $4.43M | 0.13% |
378,932
-413,683
| -52% | -$4.84M |
|
86
Biohaven
BHVN
$1.68B
| $4.43M | 0.13% |
127,558
+574
| +0.5% | +$19.9K |
|
87
Pliant Therapeutics
PLRX
$98.2M
| $4.14M | 0.12% |
384,996
| – | – |
|
88
Pulmonx
LUNG
$67.6M
| $4.14M | 0.12% |
652,400
| – | – |
|
89
Perspective Therapeutics
CATX
$238M
| $4M | 0.12% |
+401,196
| New | +$4M |
|
|
AUTL
90
Autolus Therapeutics
AUTL
$375M
| $3.59M | 0.11% |
1,032,988
| – | – |
|
91
ESSA Pharma
EPIX
$11M
| $3.56M | 0.11% |
677,005
| – | – |
|
92
Aclaris Therapeutics
ACRS
$217M
| $3.03M | 0.09% |
2,753,495
| – | – |
|
93
Gossamer Bio
GOSS
$573M
| $2.94M | 0.09% |
3,266,960
| – | – |
|
94
Xilio Therapeutics
XLO
$36.5M
| $2.85M | 0.09% |
3,003,259
+1,562,500
| +108% | +$1.48M |
|
95
Sagimet Biosciences
SGMT
$231M
| $2.69M | 0.08% |
787,808
+17,137
| +2% | +$58.6K |
|
96
Leap Therapeutics
LPTX
$11.9M
| $2.48M | 0.07% |
1,266,546
+354,609
| +39% | +$695K |
|
|
ADAP
97
Adaptimmune Therapeutics
ADAP
$12.9M
| $2.36M | 0.07% |
2,425,468
| – | – |
|
|
VIGL
98
DELISTED
Vigil Neuroscience
VIGL
| $1.89M | 0.06% |
471,958
| – | – |
|
99
Compugen
CGEN
$132M
| $1.66M | 0.05% |
989,990
-300,000
| -23% | -$504K |
|
|
SPRB
100
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| $1.35M | 0.04% |
2,609,125
| – | – |
|